{"id":542212,"date":"2021-05-07T14:08:01","date_gmt":"2021-05-07T14:08:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=542212"},"modified":"2021-05-07T14:08:01","modified_gmt":"2021-05-07T14:08:01","slug":"advanced-liver-cancer-market-size-and-share-trends-epidemiology-and-market-research-forecast-2030-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/advanced-liver-cancer-market-size-and-share-trends-epidemiology-and-market-research-forecast-2030-delveinsight_542212.html","title":{"rendered":"Advanced Liver Cancer Market Size and Share, Trends, Epidemiology and Market Research Forecast 2030 | DelveInsight"},"content":{"rendered":"
\"Advanced<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cAdvanced Liver Cancer \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u2033 report delivers an in-depth understanding of the Advanced Liver Cancer, historical and forecasted epidemiology as well as the Advanced Liver Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “Advanced Liver Cancer – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>.<\/p>\n

DelveInsight’s “Advanced Liver Cancer – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>″ report delivers an in-depth understanding of the Advanced Liver Cancer, historical and forecasted epidemiology as well as the Advanced Liver Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    As per the American Cancer Society, estimates for primary liver cancer and intrahepatic bile duct cancer in the United States for 2019 are: <\/p>\n<\/li>\n

      \n
    1. \n

      About 42,030 new cases (29,480 in men and 12,550 in women) will be diagnosed <\/p>\n<\/li>\n

    2. \n

      About 42,030 new cases (29,480 in men and 12,550 in women) will be diagnosed<\/p>\n<\/li>\n<\/ol>\n

    3. \n

      According to the Centers for Disease Control and Prevention, estimates that, about 33,000 people get liver cancer, and about 26,000 people die from the disease each year in the United States<\/p>\n<\/li>\n<\/ol>\n

      Key benefits of the report:<\/strong><\/p>\n

      1. Advanced Liver Cancer market report covers a descriptive overview and comprehensive insight of the Advanced Liver Cancer epidemiology and Advanced Liver Cancer market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

      2. Advanced Liver Cancer market report provides insights on the current and emerging therapies.<\/p>\n

      3. Advanced Liver Cancer market report provides a global historical and forecasted market covering drug outreach in 7 MM.<\/p>\n

      4. Advanced Liver Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Advanced Liver Cancer market.<\/p>\n

      Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/advanced-liver-cancer-market<\/span><\/a><\/strong><\/p>\n

      Advanced Liver Cancer: Overview<\/strong><\/p>\n

      Advanced Liver Cancer is a stage IV Liver Cancer in which the cancer has spread to nearby lymph nodes and may have grown into nearby blood vessels or organs. It does not often metastasize but when it does, it is most likely to spread to the lungs and bones. It is further categorized into IVA and IVB stages. In stage IVA the cancer has grown into blood vessels or the organs around the liver and has spread to lymph nodes but not to other parts of the body. While in stage IVB the cancer spread to another part of the body such as the lungs or bones. <\/p>\n

      The key players involved in the Advanced Liver Cancer market:<\/strong><\/a><\/p>\n

        \n
      1. \n

        Benhealth Biopharmaceutical (Shenzhen), <\/p>\n<\/li>\n

      2. \n

        Can-Fite BioPharma<\/p>\n<\/li>\n

      3. \n

        Millennium Pharmaceuticals<\/p>\n<\/li>\n<\/ol>\n

        The launch of the emerging therapies is expected to significantly impact the Advanced Liver Cancer treatment scenario in the upcoming years:-<\/strong><\/p>\n

        Drugs covered<\/strong><\/p>\n

          \n
        1. \n

          CIK and CD3-MUC1<\/p>\n<\/li>\n

        2. \n

          CF102<\/p>\n<\/li>\n

        3. \n

          MLN0128<\/p>\n<\/li>\n<\/ol>\n

          Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/advanced-liver-cancer-market<\/span><\/a><\/strong><\/strong><\/p>\n

          Table of Contents<\/strong><\/p>\n

          1. Report Introduction<\/p>\n

          2. Executive Summary<\/p>\n

          3. SWOT analysis<\/p>\n

          4. Advanced Liver Cancer Patient Share (%) Overview at a Glance<\/p>\n

          5. Advanced Liver Cancer Market Overview at a Glance<\/p>\n

          6. Advanced Liver Cancer Disease Background and Overview<\/p>\n

          7. Advanced Liver Cancer Epidemiology and Patient Population<\/p>\n

          8. Country-Specific Patient Population of Advanced Liver Cancer<\/p>\n

          9. Advanced Liver Cancer Current Treatment and Medical Practices<\/p>\n

          10. Unmet Needs<\/p>\n

          11. Advanced Liver Cancer Emerging Therapies<\/p>\n

          12. Advanced Liver Cancer Market Outlook<\/p>\n

          13. Country-Wise Advanced Liver Cancer Market Analysis (2017–2030)<\/p>\n

          14. Market Access and Reimbursement of Therapies<\/p>\n

          15. Market drivers<\/p>\n

          16. Market barriers<\/p>\n

          17. Appendix<\/p>\n

          18. Advanced Liver Cancer Report Methodology<\/p>\n

          19. DelveInsight Capabilities<\/p>\n

          20. Disclaimer<\/p>\n

          21. About DelveInsight<\/p>\n

          Related Reports:<\/strong><\/p>\n

          Adenoid Cystic Carcinoma (ACC) – Epidemiology Forecast to 2030<\/strong><\/p>\n

          DelveInsight’s ‘Advanced Liver Cancer – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Advanced Liver Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

          Media Contact<\/span>
          Company Name:<\/strong>           DelveInsight Business Research LLP<\/a>
          Contact Person:<\/strong> Kritika Rehani
          Email:<\/strong>           Send Email<\/a>
          Phone:<\/strong> 9193216187
          Address:<\/strong>304 S. Jones Blvd #2432
          City:<\/strong> Las Vegas
          State:<\/strong> Nevada
          Country:<\/strong> United States
          Website:<\/strong>           https:\/\/www.delveinsight.com\/<\/a><\/p>\n

          <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

          DelveInsight Business Research LLP DelveInsight\u2019s \u201cAdvanced Liver Cancer \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u2033 report delivers an in-depth understanding of the Advanced Liver Cancer, historical and forecasted epidemiology as well as the Advanced Liver Cancer market trends in the … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-542212","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=542212"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542212\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=542212"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=542212"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=542212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}